<div id="readability-page-1" class="page"><div> <h2>Key Points</h2><ul><li>Pfizer could flourish under a Warsh-led Fed for several reasons.</li><li>However, the drugmaker won't be a slam-dunk winner, in part because of its debt and patent cliff.</li><li>The biggest challenge is that no one knows for sure what changes Warsh will make.</li><li>10 stocks we like better than Pfizer ›</li></ul>Savvy investors know that change creates opportunities. And a major change is underway at the nation's central bank. Kevin Warsh is now the new Federal Reserve Chair, taking the baton from Jerome Powell. Warsh has publicly called for &#34;regime change&#34; at the Fed, a term that could signal significant policy shifts.Which stocks should investors consider buying with Warsh in charge? Pfizer (NYSE: PFE) looks like an intriguing candidate. The big drugmaker offers a juicy dividend yield of 6.6%. Its valuation is attractive, with shares trading at only 8.9 times forward earnings. Could Pfizer be the perfect stock to own with Warsh heading the Fed?Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. Continue »<img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg3MjE2Mi9mZWQtY2hhaXIta2V2aW4td2Fyc2gtb2ZmaWNpYWwtd2hpdGUtaG91c2UtcGhvdG8tYnktZGFuaWVsLXRvcm9rLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="700" height="466" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg3MjE2Mi9mZWQtY2hhaXIta2V2aW4td2Fyc2gtb2ZmaWNpYWwtd2hpdGUtaG91c2UtcGhvdG8tYnktZGFuaWVsLXRvcm9rLmpwZyZ3PTcwMA"/>Fed Chair Kevin Warsh. Image source: Official White House Photo by Daniel Torok. <h2>Why Pfizer could flourish under a Warsh-led Fed</h2>No one knows for sure what the implications will be with Warsh serving as Fed chair. We're likely entering a period of uncertainty. Volatility will increase for some stocks. However, healthcare stocks such as Pfizer tend to hold up quite well during such times.Regardless of what happens with monetary policy, patients will continue to need critical medications -- and physicians will continue prescribing them. Pfizer's sales shouldn't be affected much, if at all, by interest rate changes under Warsh's watch.Investors often find dividend stocks more appealing when markets are turbulent. Pfizer's ultra-high dividend yield, along with its 16 consecutive years of dividend increases and 350 consecutive quarterly dividend payments, could be attractive if Warsh's &#34;regime change&#34; leads to stock market choppiness. The pharmaceutical company's low valuation could help, too. Rising inflation could force the Fed to raise interest rates. Rising rates usually hit expensive growth stocks the hardest. Value stocks, on the other hand, are more insulated from the effects of increasing interest rates.<h2>Why Pfizer may be less than ideal with Warsh in charge</h2>However, Pfizer won't be a slam-dunk winner with Warsh at the helm of the Federal Reserve. For one thing, if rates indeed move higher, Pfizer's dividend could become less appealing relative to the higher, relatively risk-free yields of U.S. Treasuries. Investors may become more skittish about Pfizer's high dividend payout ratio of 131%.Pfizer also has $64.7 billion of debt. If the company has to refinance maturing debt at higher rates, its interest expense will increase, putting pressure on margins.Probably the biggest reason Pfizer may not be the perfect stock to own with Warsh serving as Fed chair, though, is the multiple challenges the company faces. Pfizer's patent cliff stands at the top of the list. Cancer drug Adcetris and autoimmune disease drug Xeljanz lose U.S. patent exclusivity in 2026. Next year is even worse, with patents expiring on Pfizer's two biggest blockbusters, the blood thinner Eliquis and the breast cancer therapy Ibrance. Prostate cancer drug Xtandi also loses patent exclusivity in 2027. Because of this patent cliff, Pfizer is heavily dependent on its pipeline for future growth. However, there's always a risk that experimental drugs in development will flop in clinical trials or be rejected by regulatory agencies. Meanwhile, competitors are developing products that could threaten Pfizer's existing drugs.<h2>The uncertainty factor</h2>Even if we could sweep all of Pfizer's issues under the rug, there's still one overriding reason why we can't declare the stock as a perfect pick to own with Warsh leading the Fed. That reason has nothing to do with Pfizer; instead, it's about Warsh himself. As mentioned earlier, no one knows exactly what policy changes the new Fed chair will make or how quickly he will be able to implement those changes.Warsh probably doesn't fully know the answers to these questions yet, either. He can't make monetary policy decisions unilaterally. It's possible (and perhaps probable) that Warsh will encounter significant pushback from other members of the Fed if he tries to make a drastic change. Macroeconomic realities could also prevent him from advancing some of his ideas.This uncertainty factor makes it impossible to declare any stock as the ideal choice to own with a Warsh-led Fed. But while Pfizer may not be a perfect stock, it should still be attractive to income investors seeking juicy, reliable dividends.<h2>Should you buy stock in Pfizer right now?</h2> Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!* Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&amp;P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of June 1, 2026. Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

The article analyzes whether Pfizer is an ideal stock to hold under new Fed Chair Kevin Warsh. While Pfizer's high dividend yield and low valuation may appeal during potential market volatility, risks include its heavy debt load, upcoming patent cliffs for key drugs like Eliquis, and the uncertainty of Warsh's actual policy shifts. Ultimately, while not a 'slam-dunk' winner due to these challenges, it remains attractive for income investors.

- Pfizer may benefit under new Fed Chair Kevin Warsh due to its high dividend yield and low valuation, making it appealing in uncertain markets.  
- However, challenges like a $64.7 billion debt, upcoming patent expirations, and potential volatility from policy changes could hinder its performance.  
- Uncertainty around Warsh’s policy decisions adds further risk, leading investors to consider other stocks that may yield better returns.

Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?